Global Deuterated Drugs Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI10241126

Publication Date:

October 22, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Manufacturing (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

According to this study, the global Deuterated Drugs market size will reach US$ million by 2030.
A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Deuterated Drugs market by product type, application, key players and key regions and countries.
Segmentation by product type:
Austedo
Zepsun
Others
Segmentation by Application:
Huntington'S Disease (HD)
Tardive Dyskinesia (TD)
Cancer
Others
This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Teva
Suzhou Zelgen Biopharmaceuticals
Concert Pharmaceuticals
Vertex Pharmaceuticals
Hinova Pharma
Otsuka Pharmaceutical (Avanir)
Poxel SA (DeuteRx)

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Deuterated Drugs Market Size 2024-2030
2.1.2 Deuterated Drugs Market Size CAGR by Region
2.2 Deuterated Drugs Segment by Type
2.2.1 Austedo
2.2.2 Zepsun
2.2.3 Others
2.3 Deuterated Drugs Market Size by Type
2.3.1 Global Deuterated Drugs Market Size Market Share by Type (2024-2030)
2.3.2 Global Deuterated Drugs Market Size Growth Rate by Type (2024-2030)
2.4 Deuterated Drugs Segment by Application
2.4.1 Huntington'S Disease (HD)
2.4.2 Tardive Dyskinesia (TD)
2.4.3 Cancer
2.4.4 Others
2.5 Deuterated Drugs Market Size by Application
2.5.1 Global Deuterated Drugs Market Size Market Share by Application (2024-2030)
2.5.2 Global Deuterated Drugs Market Size Growth Rate by Application (2024-2030)
3 Deuterated Drugs Key Players
3.1 Date of Key Players Enter into Deuterated Drugs
3.2 Key Players Deuterated Drugs Product Offered
3.3 Key Players Deuterated Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Deuterated Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 Deuterated Drugs by Regions
4.1 Deuterated Drugs Market Size by Regions (2024-2030)
4.2 United States Deuterated Drugs Market Size Growth (2024-2030)
4.3 China Deuterated Drugs Market Size Growth (2024-2030)
4.4 Europe Deuterated Drugs Market Size Growth (2024-2030)
4.5 Rest of World Deuterated Drugs Market Size Growth (2024-2030)
5 United States
5.1 United States Deuterated Drugs Market Size by Type (2024-2030)
5.2 United States Deuterated Drugs Market Size by Application (2024-2030)
6 Europe
6.1 Europe Deuterated Drugs Market Size by Type (2024-2030)
6.2 Europe Deuterated Drugs Market Size by Application (2024-2030)
7 China
7.1 China Deuterated Drugs Market Size by Type (2024-2030)
7.2 China Deuterated Drugs Market Size by Application (2024-2030)
8 Rest of World
8.1 Rest of World Deuterated Drugs Market Size by Type (2024-2030)
8.2 Rest of World Deuterated Drugs Market Size by Application (2024-2030)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Key Investors in Deuterated Drugs
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 鈥︹€�
11 Key Players Analysis
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Deuterated Drugs Product Offered
11.1.3 Teva Deuterated Drugs Market Size (2024 VS 2030)
11.1.4 Teva Main Business Overview
11.1.5 Teva News
11.2 Suzhou Zelgen Biopharmaceuticals
11.2.1 Suzhou Zelgen Biopharmaceuticals Company Details
11.2.2 Suzhou Zelgen Biopharmaceuticals Deuterated Drugs Product Offered
11.2.3 Suzhou Zelgen Biopharmaceuticals Deuterated Drugs Market Size (2024 VS 2030)
11.2.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
11.2.5 Suzhou Zelgen Biopharmaceuticals News
11.3 Concert Pharmaceuticals
11.3.1 Concert Pharmaceuticals Company Details
11.3.2 Concert Pharmaceuticals Deuterated Drugs Product Offered
11.3.3 Concert Pharmaceuticals Deuterated Drugs Market Size (2024 VS 2030)
11.3.4 Concert Pharmaceuticals Main Business Overview
11.3.5 Concert Pharmaceuticals News
11.4 Vertex Pharmaceuticals
11.4.1 Vertex Pharmaceuticals Company Details
11.4.2 Vertex Pharmaceuticals Deuterated Drugs Product Offered
11.4.3 Vertex Pharmaceuticals Deuterated Drugs Market Size (2024 VS 2030)
11.4.4 Vertex Pharmaceuticals Main Business Overview
11.4.5 Vertex Pharmaceuticals News
11.5 Hinova Pharma
11.5.1 Hinova Pharma Company Details
11.5.2 Hinova Pharma Deuterated Drugs Product Offered
11.5.3 Hinova Pharma Deuterated Drugs Market Size (2024 VS 2030)
11.5.4 Hinova Pharma Main Business Overview
11.5.5 Hinova Pharma News
11.6 Otsuka Pharmaceutical (Avanir)
11.6.1 Otsuka Pharmaceutical (Avanir) Company Details
11.6.2 Otsuka Pharmaceutical (Avanir) Deuterated Drugs Product Offered
11.6.3 Otsuka Pharmaceutical (Avanir) Deuterated Drugs Market Size (2024 VS 2030)
11.6.4 Otsuka Pharmaceutical (Avanir) Main Business Overview
11.6.5 Otsuka Pharmaceutical (Avanir) News
11.7 Poxel SA (DeuteRx)
11.7.1 Poxel SA (DeuteRx) Company Details
11.7.2 Poxel SA (DeuteRx) Deuterated Drugs Product Offered
11.7.3 Poxel SA (DeuteRx) Deuterated Drugs Market Size (2024 VS 2030)
11.7.4 Poxel SA (DeuteRx) Main Business Overview
11.7.5 Poxel SA (DeuteRx) News
...
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂